Comprehensive Structured Transition Program with Dedicated Transition Navigator Reduced Lost to Follow-up and Improved Medication Adherence in Sickle Cell Disease and Thalassemia Adolescents and Young Adults
Brooke Allemang(University of Toronto), Kevin H.M. Kuo(University Health Network), Colleen Johnson(University Health Network), Isaac Odame(Hospital for Sick Children), Melina Cheong(University of Toronto), Patrina Cheung(University of Toronto), Kate Allan(Waitemata District Health Board), Richard Ward(University of Tennessee Health Science Center), Suzan Williams(Hospital for Sick Children)
Cited by 4
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Online haemodiafiltration: definition, dose quantification and safety revisited
|Nephrology Dialysis Transplantation|2013|256
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162